(Q61900024)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

meta-analysis

0 references

title

Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Diana Giannarelli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Alessandra Felici

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Cecilia Nisticò

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Barbara Vanni

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Federica Cuppone

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Francesco Cognetti

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Edmondo Terzoli

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

William P Peters

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

language of work or name

English

0 references

publication date

1 February 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

672-679

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20757

7 January 2021

Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20757

7 January 2021

Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20757

7 January 2021

Meta-analyses of randomised clinical trials in oncology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20757

7 January 2021

Confronting publication bias: a cohort design for meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20757

7 January 2021

Interpreting Measures of Treatment Effect in Cancer Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20757

7 January 2021

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20757

7 January 2021

Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20757

7 January 2021

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20757

7 January 2021

Taxane containing regimens for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20757

7 January 2021

Meta-analysis of the literature or of individual patient data: is there a difference?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20757

7 January 2021

Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20757

7 January 2021

Identifiers

DOI

10.1002/CNCR.20757

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15637696%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference